Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Stock Information for Simulations Plus Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Simulations Plus Inc.

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
Simulations Plus, Inc. Investigated by the Portnoy Law Firm
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
SLP Investor News: If You Have Suffered Losses in Simulations Plus, Inc. (NASDAQ: SLP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.